Global Excellence in Animal Health
Welcome to the Bimeda® US website. Bimeda® is a leading global manufacturer, marketer and distributor of animal health products and veterinary pharmaceuticals.
Bimeda® US headquarters are based in Schaumburg, Illinois. The Bimeda® US product portfolio focuses on five key categories: ecto- and endo-parasiticides, water soluble antimicrobials, injectables and nutritional products. Bimeda® is focused on providing a comprehensive, customer-driven service and selling consistently high-quality products at a market-conscious price level.
Through ongoing expansion and strategic acquisition, Bimeda® has established markets in more than eighty countries worldwide and has R&D, manufacturing and distribution capabilities across Europe, North America, South America, Africa, Asia and Australia. Bimeda® employs over employees worldwide and has its global headquarters in Dublin, Ireland.
Bimeda® is a proud member of the GADA (Generic Animal Drug Alliance). GADA is an independent, professional trade association that represents the interests of generic animal drug companies. GADA supports the education of veterinarians and the general public on the topic of generic drugs safety, quality process and FDA approval. With the support of GADA, generic animal drug companies like Bimeda® ensure that veterinarian and animal owners have access to safe and effective generic drugs.
To learn more about Bimeda’s global presence, why not read our corporate brochure.
Latest News
14 April 2025
Schaumburg, Illinois (APRIL 14, 2025) – Bimeda is pleased to announce an expansion to its product portfolio with the addition of SecureCattle, an analog of the naturally secreted bovine appeasing pheromone (BAP). SecureCattle is a high quality, pour-...
11 March 2025
AquaTactics, Bimeda's Washington-based aquaculture division, is excited to announce its entry into the autogenous fish vaccine sector, following USDA approval. Autogenous fish vaccine production and wet-lab safety testing will take place at Bim...
13 November 2024
Schaumburg, Illinois – Bimeda is excited to announce the expansion of its anti-parasitic portfolio with the introduction of MoxiSolv Injection (moxidectin). MoxiSolv stands out as the only FDA-approved, bioequivalent alternative to Cydectin® Injectab...